Harbour Capital Advisors LLC Takes Position in Merus (NASDAQ:MRUS)

Harbour Capital Advisors LLC bought a new position in shares of Merus (NASDAQ:MRUS) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 8,350 shares of the biotechnology company’s stock, valued at approximately $360,000.

A number of other hedge funds also recently added to or reduced their stakes in MRUS. Wellington Management Group LLP increased its position in shares of Merus by 73.6% during the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock worth $144,260,000 after acquiring an additional 1,224,573 shares during the period. Marshall Wace LLP increased its holdings in Merus by 813.3% during the 2nd quarter. Marshall Wace LLP now owns 957,952 shares of the biotechnology company’s stock worth $56,682,000 after purchasing an additional 853,060 shares during the period. Logos Global Management LP acquired a new stake in Merus in the 2nd quarter valued at about $50,294,000. Novo Holdings A S purchased a new position in shares of Merus in the 2nd quarter valued at about $39,940,000. Finally, FMR LLC increased its stake in shares of Merus by 10.4% during the third quarter. FMR LLC now owns 6,873,926 shares of the biotechnology company’s stock worth $343,421,000 after buying an additional 648,994 shares during the period. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Trading Down 7.8 %

Shares of MRUS stock opened at $40.45 on Tuesday. Merus has a 12-month low of $31.27 and a 12-month high of $61.61. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -10.24 and a beta of 1.10. The stock has a 50 day simple moving average of $44.96 and a 200-day simple moving average of $49.63.

Merus (NASDAQ:MRUS) last released its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The business had revenue of $11.77 million during the quarter, compared to analyst estimates of $9.11 million. On average, equities analysts forecast that Merus will post -3.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MRUS has been the subject of several recent analyst reports. Guggenheim reaffirmed a “buy” rating and set a $109.00 price objective (down from $111.00) on shares of Merus in a research report on Tuesday, December 3rd. Citigroup boosted their target price on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a report on Monday, December 9th. UBS Group started coverage on Merus in a research note on Thursday, October 24th. They set a “buy” rating and a $72.00 price target on the stock. The Goldman Sachs Group began coverage on Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $85.00 price target on shares of Merus in a research note on Monday, December 9th. One analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Merus has a consensus rating of “Buy” and an average target price of $85.64.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.